ASSOCIATED WITH GANGLIOSIDES RECOMBINANT ANTIBODIES AND THEIR APPLICATION IN DIAGNOSTICS AND TREATMENT OF TUMORS

摘要

This invention relates to the production of modified antibodies using recombinant DNA technology from mouse monoclonal antibody P3 (MAb P3), produced by a hybridoma cell line deposited in accordance with the Budapest Treaty with access number ECACC 94113026, and from anti-idiotypic mouse monoclonal antibody 1E10 (MAai 1E) produced by a hybridoma cell line with the deposit number ECACC 97112901, in order to produce monoclonal antibodies that retain the biological function of a specific binding antigens of the original antibodies, but at the same time less immunogenic. The chimeric antibodies of the present invention contain the variable domains of a mouse immunoglobulin and constant regions of a human immunoglobulin; and when humanized, along with the content of the constant regions of human immunoglobulins, they are modified in the region of the mouse regions of the immunoglobulin reading frame (FR) and, in particular, in those areas that could be in the antigenic site for T-cells, thus several These FRs are also derived from human immunoglobulin. These antibodies can be used in the diagnosis and treatment of various types of tumors. This invention also relates to the use of these antibodies for therapeutic and diagnostic purposes.